Further Warning on SGLT2 Inhibitor Use and DKA Risk in COVID-19
A cluster of cases of diabetic ketoacidosis in which there was no hyperglycemia supports recommendations that SGLT2 inhibitors be discontinued in patients with type 2 diabetes who become ill with COVID-19.